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Abstract: The Schellman motif is a widely observed helix terminating structural motif in proteins,
which is generated when the C-terminus residue adopts a left-handed helical (aL) conformation. The
resulting hydrogen-bonding pattern involves the formation of an intramolecular 63 1 interaction.
This helix terminating motif is readily mimicked in synthetic helical peptides by placing an achiral
residue at the penultimate position of the sequence. Thus far, the Schellman motif has been
characterized crystallographically only in peptide helices of length 7 residues or greater. The
structure of the hexapeptide Boc–Pro–Aib–Gly–Leu–Aib–Leu–OMe in crystals reveal a short
helical stretch terminated by a Schellman motif, with the formation of 63 1 C-terminus hydrogen
bond. The crystals are in the space group P212121 with a 5 18.155(3) Å, b 5 18.864(8) Å, c
5 11.834(4) Å, and Z 5 4 . The final R1 and wR2 values are 7.68 and 14.6%, respectively , for 1524
observed reflections [Fo $ 3s(Fo)]. A 63 1 hydrogen bond between Pro(1)CO z z z Leu(6)NH and
a 53 2 hydrogen bond between Aib(2)CO z z z Aib(5)NH are observed. An analysis of the available
oligopeptides having an achiral Aib residue at the penultimate position suggests that chain length
and sequence effects may be the other determining factors in formation of Schellman motifs.
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INTRODUCTION
Helical structures in polypeptides are characterized by
several contiguous residues in the polymer chain
adopting backbone dihedral angles in a limited region
of conformational space.1,2 In the case of right-
handed a-helices the characteristic Ramachandran an-
gles are f ' 257°, c, ' 247°3 Helix termination is
then achieved by residues at the N- and C-termini
adopting nonhelical conformations. Major regions of
allowed conformational space for helix terminating
L-amino acid residues lie in the extended (f
' 2120°, c ' 120°) and semiextended (f ' 260°,
c ' 120°) region of the Ramachandran map.4 An
especially important class of terminating residue con-
formations was recognized by Charlotte Schellman,5
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who noted that helices in proteins were frequently
terminated by the C-terminus residue adopting left-
handed helical (aL) conformations (f ' 60°, c
' 30°). This stereochemical feature, where helix ter-
mination occurs by chiral reversal of f,c values, is
widely observed in protein crystal structures6–9 and
has been termed the Schellman motif .7 The terminat-
ing residue is invariably an achiral amino acid Gly
and to a much lesser extent Asn, which has a rela-
tively high propensity for aL-conformations.10
In synthetic peptides, Schellman motifs have been
widely characterized in crystal structures of peptide
helices containing achiral residues, almost invariably
a-aminoisobutyric acid (Aib), at the penultimate po-
sition at the C-terminus.11 In principle the Schellman
motif can be formed by a succession of residues with
the conformational motif aR–aR–aR–aL and could
therefore be observed even in a protected tetrapeptide
that has hydrogen-bonding CO and NH functions in
the terminal protecting groups (e.g., Boc and NHMe
at the N- and C-terminus, respectively). Thus far, the
Schellman motif has been characterized crystallo-
graphically only in peptide helices of length 7 resi-
dues or greater.
We describe below the crystal structure of a syn-
thetic hexapeptide Boc–Pro–Aib–Gly–Leu–Aib–
Leu–OMe, related to the C-terminal segment of the
peptide antibiotic efrapeptin12,13 in which a short he-
lical segment is terminated by chiral reversal. The
structure also reveals an interesting hydration pattern,
which is of relevance in the context of recent discus-
sions on the role of hydrated peptide backbones in the
folding process.14,15
EXPERIMENTAL PROCEDURE
Crystallization and X-Ray Diffraction
Data Collection
The peptide Boc–Pro–Aib–Gly–Leu–Aib–Leu–OMe (1)
was synthesized by conventional solution phase procedures,
and purified by medium pressure liquid chromatography on
a 40–60m, C18 column using methanol–water gradients for
elution. Crystals of the peptide 1 were grown from a meth-
anol/water solution by slow evaporation. The x-ray diffrac-
tion data were collected from dry crystals of peptide 1 on an
automated four circle diffractometer. Unit cell parameters
were obtained and refined by least squares fit of the angular
settings of 25 accurately determined reflections in the range
of 0° , u ,25°. Three-dimensional MoKa (l 5 0.7107 Å)
intensity data were collected upto 2u 5 54°. An v -2u scan
with variable scan speed was used. Three reflections, mon-
itored after every 15 minutes of x-ray exposure, showed less
than 3% variation in intensities. Lorentz polarization cor-
rections were applied, but not the absorption corrections
[m(1) 5 0.08 mm21]. All the parameters relevant to the data
collection are listed in Table I.
Structure Solution and Refinement
The crystal structure of 1 was determined by the vector
search method16 followed by partial structure expansion.17
Patterson maps were computed using SHELX-86.18 The
computer program PATSEE16 was used for proper orienta-
tion and translation of the fragment used as the model in the
vector or Patterson search. Partial structure expansion was
done using SHELX-86.
The approach of using direct methods was not successful
in yielding the structure. Subsequent attempts using the
vector search methods with models of different helical
conformations or Schellman motif modules were unsuccess-
ful. The use of the backbone [CO(Aib)–Pro–Ala–NH(Aib)]
of the underlined segment of the sequence Boc–Trp–Ile–
Ala–Aib–Ile–Val–Aib–Leu–Aib–Pro–Ala–Aib–Pro–Aib–
Pro–Phe–OMe19 as a model fragment was successful in
determining the structure. A sharpened Patterson map and
250 largest uEu values were used in the vector search
method. Proper orientation and translation were identified
Table I Data Collection and Refinement Parameters
for Peptide 1
Empirical formula C33O9N6H57
Crystal habit Clear rectangular
Crystal size (mm) 0.4 3 0.2 3 0.1
Crystallizing solvent CH3OH/H2O
Space group P212121
Cell parameters
a (Å) 18.155(5)
b (Å) 18.864(8)
c (Å) 11.834(4)
Volume (Å3) 4052.9
Z 4
Molecules/asym. unit 1
Cocrystallized solvent None
Molecular weight 698.8
Density (g/cm) (calc) 1.145
F(000) 1512
Radiation (Å) MoKa (l 5 0.7107)
2u Range (°) 50
Scan type v 2 2u
Scan speed Variable
Independent reflections 2987
Observed reflections.
[uFu . 3 s(F)]
1524
Goodness-of-fit (S) 1.18
Drmax (eÅ23) 0.18
Drmin (eÅ23) 20.25
Final R 7.68%
Final RW 14.6%
Data-to-parameter ratio 3 : 1
on the basis of highest rotational figure of merit (RFOM)
and highest combined figure of merit (CFOM).16
The fragment containing 14 atoms was then used in the
partial structure expansion method employing 250 reflec-
tions satisfying the criterion Eobs . 1.5 and the largest
values of Ecalc/ Eobs. The Fourier map generated revealed 45
atoms out of 48 nonhydrogen atoms in the asymmetric unit.
The remaining nonhydrogen atoms were located from the
difference Fourier map.
A full-matrix least-squares refinement was carried out
using SHELX-93.20 All the nonhydrogen atoms were ini-
tially refined isotropically. The hydrogen atoms were fixed
geometrically in the idealized positions with C—H 5 1.08
Å and N—H 5 1.08 Å, and refined in the final cycle of
refinement as riding over the atoms they are bonded. The
final R factor was 0.0768 (Rw 5 0.146) for 1524 observed
reflections, with Fo $ 3s(Fo). The function minimized
during refinement was Sw(uFo minus; Fu)2, where w 5 1/[s2
3 (Fo2) 1 (.0910 3 P)2], where P 5 [Max (Fo2, 0 ) 1 2
(Fc2]/3. The crystallographic coordinates (nonhydrogen and
hydrogen atoms) and thermal parameters of peptide 1 are
being deposited in the Cambridge Crystallographic Data
File and are also available on request from authors.*
RESULTS AND DISCUSSION
Crystal State Conformation of Peptide 1
Torsion angles and the comparative 4 3 1/5 3 1
hydrogen-bond parameters for Boc–Pro–Aib–Gly–
Leu–Aib–Leu–OMe are listed in Table II and Table
III, respectively. Figure 1 shows the stereo view of the
molecular conformation in crystals. Backbone dihe-
dral angles indicate that the first three residues Pro(1),
Aib(2), and Gly(3) form a right-handed helical turn,
whereas Leu(4) and Aib(5) residues fall in the bridge
region and the left-handed helical regions of the Ra-
machandran plot (Table III). Inspection of the param-
eters for potential 4 3 1 and 5 3 1 interactions
suggest that the molecule possesses three relatively
weak 4 3 1 hydrogen bonds CO(0) z z z NH(3),
CO(1) z z z NH(4), and CO(2) z z z NH(5). While the
CO(0) z z z NH(4) and CO(1) z z z NH(5) distances are
comparable to the distances normally observed for 4
3 1 hydrogen bonds, the O z z z H distances are
significantly longer. Although all the intramolecular
hydrogen-bonding interactions observed in the helical
turn are relatively weak, the helix terminating 6 3 1
hydrogen bond formed between CO(1) z z z NH(6) is
characterized by much shorter N z z z O (3.02 Å) and
O z z z H (2.18 Å) distances. The Schellman motif is
formed by the chiral reversal at Aib(5) and backbone
distortions at Leu(4) leading to both 63 1 (C16) and
5 3 2 (C10) interactions. This feature has been iden-
tified as a “paper clip” in protein structures by Milner-
White.7 The 43 1 hydrogen bond encased within the
Schellman motif module appears to represent a rela-
tively weak interaction as suggested by the longer
N z z z O (3.41 Å) and H z z z O (2.59 Å) distances, a
feature that has also been noted earlier.11
Side-Chain Conformations
Both Leu side chains assume g2(tg2) conformations.
Although, the most widespread leucine side-chain
conformations in peptides as well as in proteins are
g2(tg2) and t(g1t), the former is most prevalent.21–23
The pyrrolidine ring torsional angles for Pro(1) (Table
II, footnote e) establish a Cg-exo puckering for the
five-membered ring.24
Packing
Figure 2 shows the molecular packing in crystals. All
the symmetry-related molecules in the unit cell are
held together by weak van der Waals interactions.
Molecules are arranged head-to-tail in the crystal
along the c axis, with a bridging water molecule
inserted between translationally related peptides (Fig-
ure 2). Hydrogen bonds are formed involving the
water molecule, which are bifurcated in nature
* Supplementary material consisting of coordinates (nonhydro-
gen and hydrogen atoms), bond lengths, bond angles, and thermal
parameters will be deposited with the Cambridge Structural Data
Base, University Chemical Laboratory, Lensfield Road, Cambridge
CB21EW, UK. Observed and calculated structure factors can be
obtained on request.
Table II Torsion Anglesa (deg) in Peptide 1
Residue f C v x1 x2
Pro(1)e 254b 242 2175
Aib(2) 257 243 2177
Gly(3) 274 216 178
Leu(4) 2100 6 180 269 168, 269
Aib(5) 60 42 178
Leu(6) 2113 166c 167d 258 169, 269
a The definition of torsion angles for rotation about bonds of the
peptide backbone (f, w, and v) and about bonds of the amino acid
side chains (x1, x2) are as suggested by the IUPAC-IUB Commis-
sion on Biochemical Nomenclature (1970).30 Estimated standard
deviations ; 1.0°.
b C9(0)ON(1)OCa(1)OC9(1).
c N(6)OCa(6)OC9(6)OO(OMe).
d Ca(6)OC9(6)OO(OMe)OC(OMe).
e The pyrrolidine ring torsion angles for Pro(1) are (xn, de-
grees) x1(NOCaOCbOCg) 5 224, x2(CaOCbOCgOCd) 5 29,
x3(CbOCgOCdON) 5 222, x4(CgOCdONOCa) 5 7, and
u(CdONOCaOCb) 5 10.
[NH(2) z z z W z z z CO(4) and NH(2) z z z W z z z CO(5)]
(Table III). Helical peptides in crystals have almost
always been observed to pack in head-to-tail motifs
that result in long rods or columns of helices through-
out the crystal.25,26 In crystals, where the succeeding
a- and 310-helices in a column are in good register
FIGURE 1 Stereo view of peptide 1 in crystals. Intramolecular hydrogen bonds are indicated by
broken lines.
Table III Parameters for Potential Hydrogen Bonds in the Structure 1
Type Donor Acceptor
N. . .O H. . .O CAO. . .H CAO. . .N O. . .HN
Distance (Å) Angle (deg)
Intramolecular
4 3 1b N(3) O(0) 3.14 2.53 115 125 129
4 3 1b N(4) O(1) 3.06 2.35 102 112 141
4 3 1b N(5) O(2) 3.41 2.59 103 105 161
4 3 1 N(6) O(3) 6.43 5.86 44 50 128
5 3 1 N(4) O(0) 3.38 2.74 143 154 132
5 3 1 N(5) O(1) 3.22 2.89 149 163 105
5 3 1 N(6) O(2) 4.87 4.18 84 91 140
6 3 1b N(6) O(1) 3.02 2.18 147 144 167
Intermolecular Donor Acceptor Distance (Å) Angle (deg)
b N(2)a W 2.99 [N(2)a. . .W] 172[N(2)a. . .H(2). . .W]
b W O(4) 3.00 [W. . .O(4)] 149 [C9(4). . .O(4). . .W]
b W O(5) 2.93 [W. . .O(5)] 107 [C9(5). . .O(5). . .W]
a Symmetrically related by the relation ( x, y, z 2 1).
b Acceptable hydrogen bonds.31–33
with respect to each other, 3 and 2 intermolecular
NH z z z CO hydrogen bonds, respectively, can be
formed between the head of one helix and the tail of
another. In some crystals where the ends of the suc-
ceeding helices are not in good register, only 1 inter-
molecular NH z z z CO hydrogen bond may form,
expanded by water or alcohol molecules that mediate
the hydrogen bonds.27,28 Despite being in perfect reg-
ister in crystals, the helices of peptide 1 were unable
to form the two intermolecular head-to-tail hydrogen
bonds due to the reversal of helical sense at the
C-terminus as well as the absence of the NH group in
the N-terminus.
Hydration
The structure of 1 reveals a water molecule that is
simultaneously hydrogen bonded to both Leu(4) and
Aib(5) CO groups. The relative orientation of the two
CO groups is determined by the f,c torsion angles at
Aib(5), which is in fact the site of chiral reversal. The
ability of water molecules to orient hydrogen-bonding
groups in peptides has been suggested to be important
as a mechanism for the formation of short-range nu-
cleation sites in protein folding.14 Transient hydrated
structures have recently been invoked in order to
rationalize rapid conformational fluctuations in het-
eropolypeptides.15 Crystal structures of peptides fre-
quently provide a static view of specific modes of
hydration.
Schellman Motif in Short Peptides
The observation of 6 3 1 (C16) hydrogen-bonded
structures formed by chiral reversal at an achiral res-
idue, either Aib or DPhe (a,b-dehydrophenylalanine)
in synthetic peptide helices is a relatively common
feature. Table IV summarizes torsion angles for res-
FIGURE 2 Packing diagram for peptide 1 in crystals. Intermolecular hydrogen bonds are
indicated by broken lines.
idues encompassing the Schellman motif and the C-
terminal flanking residue in available crystal struc-
tures. The terminating residue (T) is defined as the
residue that adopts the aL conformation and signals
helix termination. It is clear that the f,c values at the
penultimate residue (T-1) drift into the bridge region
of the Ramachandran map, with considerable varia-
tion in the torsion angles. The terminating residue (T)
conformations are more closely clustered into left-
handed helical (aL) regions. In principle, in all these
cases the Aib/DPhe residues could have adopted right-
handed helical (aR) conformations, which would have
Table IV Torsion Angles at C-Terminus Residues in Helical Oligopeptides Having a
Terminating 6 3 1 Hydrogen Bond
Sequenceb
T 2 3 T 2 2 T 2 1 Ta T 2 1
f C f C f C f C f C
(deg) (deg) (deg) (deg) (deg)
Peptide I 278 237 259 231 2100 9 74 18 2107 31
Peptide II 277 238 256 236 288 24 60 44 55 43
Peptide IIIa 279 240 253 237 283 25 64 33 2113 37
Peptide IIIb 259 230 259 230 2114 12 52 48 2102 211
Peptide IV 265 229 270 225 2108 13 67 36 2115 144
Peptide V 263 235 270 220 2106 17 65 35 2126 167
Peptide VI 257 243 274 216 2100 6 60 42 2113 166
Peptide VII 277 29 293 14 2124 19 65 33 82
Peptide VIII 264 223 261 230 298 15 84 10 2114
Peptide IX 272 239 257 233 296 16 68 31 257 151
Peptide X 272 236 258 228 292 7 65 28 2114 22
Peptide XIc 265 223 264 224 281 216 53 49 259 239
Peptide XII 268 248 255 236 278 221 56 46 257 146
Peptide XIII 275 240 263 223 284 210 96 24 263 239
Peptide XIV 268 235 254 235 291 10 62 39 2137 2171
Peptide XVc 78 34 62 31 74 19 263 226 260 236
Peptide XVIc 254 249 278 29 280 218 56 32 85 23
Peptide XVII d 286 218 49 48 253 241
a T represents the helix terminating residue that is the site of chiral reversal. The residue preceding and following T are sequentially
numbered.
b Sequences of peptides and references in parentheses:
Peptide I: Boc–Val–Aib–Phe–Aib–Ala–Aib–Leu–OMe (Ref. 34).
Peptide II: Boc–Val–Aib–Leu–Aib–Ala–Aib–Phe–OMe (Ref. 34).
Peptide III: Boc–Val–Aib–Leu–Aib–Ala–Aib–Leu–OMe (Ref. 34).
Peptide IV: Boc–Leu–Aib–Val–Ala–Leu–Aib–Val–OMe (Ref. 35).
Peptide V: Boc–Leu–Aib–Val–Gly–Leu–Aib–Val–OMe (Ref. 11).
Peptide VI: Boc–Pro–Aib–Gly–Leu–Aib–Leu–OMe (this study).
Peptide VII: Ac–DPhe–Val–DPhe–Phe–Ala–Val–DPhe–Gly–OMe (Ref. 36).
Peptide VIII: Boc–Val–DPhe–Phe–Ala–Leu–Ala–DPhe–Leu–OH (Ref. 37).
Peptide IX: pBrBz–(Aib–Ala)5–OMe z 2H2O (from aqueous methanol solution; Ref. 38).
Peptide X: pBrBz–(Aib–Ala)6–OMe z 2H2O (Ref. 38).
Peptide XI: Boc–Leu–Aib–Val–Gly–Gly–Leu–Aib–Val–OMe (Ref. 39).
Peptide XII: Boc–(Ala–Aib)2–Ala–Glu(OBzl)–(Ala–Aib)2–Ala–OMe (Ref. 40).
Peptide XIII: Boc–Val–DPhe–Leu–Phe–Ala–DPhe–Leu–OMe (Ref. 41).
Peptide XIV: pBrBz–(Aib–Ala)5–OMe (from a DMSO–isopropanol solvent mixture; Ref. 42).
Peptide XV: Boc–D(Val–Ala–Leu–Aib–Val–Ala–Leu)–L(Val–Ala–Leu–Aib–Val–Ala–Leu)–OMe (Ref. 43).
Peptide XVI: Boc–Gly–Dpg–Gly–Gly–Dpg–Gly–NHMe (Ref. 44); Dpg: a,a-di-n-propylglycine).
Peptide XVII: Boc–Leu–Aib–Val–b–Ala–g–Abu–Leu–Aib–Val–OMe (Ref. 45).
c The potential 63 1 hydrogen bond in this case is solvated. The interaction between CO(3) and NH(8) groups in peptide XI is mediated
by the OH group of a methanol molecule. Solvent insertion (methanol) is also observed between CO(4) and NH(9) groups in peptide XV and
between CO(1) and NH(6) groups in peptide XVI.
d The definition of the backbone dihedral angles of the residues b-Ala (f 5 2130°, u 5 76°, C 5 2162°) and g-Abu (f 5 2108°, u1
5 58°, u2 5 66°, C 5 2169°) are as suggested by Banerjee and Balaram (Ref. 46).
resulted in the continuation of the right-handed helix
formed by the N-terminal segment. The difference in
energies between the continuous right-handed helical
conformation and aL-terminated structures is not ex-
pected to be appreciable, since the number of intramo-
lecular hydrogen bonds, in principle, are the same in
both the cases. In order to clarify the role of chain
length and specific sequence effects, which determine
the precise nature of the aL-terminated conformation
of peptide helices, we examined structure of peptides
that contain an achiral residue at the penultimate
position but do not form intramolecular 63 1 hydro-
gen bonds (Table V). Inspection of Table V reveals
that in the case of peptides I– IV chiral reversal is
indeed observed at the Aib residue that terminates the
helix. However, 6 3 1 hydrogen–bond formation is
precluded by the presence of a Pro residue at the
C-terminus, which lacks the hydrogen–bonding NH
function. This suggests that 63 1 hydrogen bonding
is not the driving force for the observed chiral rever-
sal. In peptide V to IX the penultimate Aib/DPhe
residues in the sequence adopt the aR conformation.
Interestingly, in these four examples the preceding
residue (T-1) is Val or Ala. Inspection of the seven-
teen examples in Table IV reveals that the T-1 residue
is Leu in 5 cases, Ala in 9 cases, and Val in 1 case. It
is possible that the Schellman motif formation or
chiral reversal at the penultimate residue in the se-
quence is facilitated by the intrinsic tendency of the
T-1 residue to adopt conformations in the bridge
region of the Ramachandran map. In order to estimate
the propensities of Leu, Val, and Ala residues for f,c
distortions in the helical region, we examined the
torsion angle distribution of these residues in the body
of available crystal structures of peptide helices. Fig-
ure 3 illustrates the observed distribution. Although
Table V Torsion Angles in Oligopeptides Lacking a 6 3 1 Hydrogen Bond,
Possessing an Achiral Residue at the Penultimate Position
Sequenceb
T 2 5 T 2 4 T 2 3 T 2 2 T 2 1 Ta T 1 1
f C f C f C f C f C f C f C
(deg) (deg) (deg) (deg) (deg) (deg) (deg)
Peptide I 255 247 266 238 261 244 259 236 273 228 50 51 262 144
Peptide II 255 248 270 228 268 248 257 242 269 228 51 53 265 214
Peptide III 259 237 276 245 259 236 258 228 281 217 46 50 270 168
Peptide IV 256 247 265 242 264 241 259 238 272 232 51 52 262 147
Peptide V 263 217 256 221 255 223 250 232 257 236 271 223 280 156
Peptide VI 268 216 260 223 261 217 246 225 269 215 255 235 154
Peptide VII 260 240 273 211 258 225 256 233 266 217 270 158
Peptide VIII 257 234 256 243 267 236 253 252 265 244 265 216 284 153
Peptide IX 251 246 274 211 2106 252 261 237 2104 256
Peptide X 256 145 55 34 56 38 60 40 253 144
Peptide XI
Molecule A 257 239 276 29 2102 259 264 234
Molecule B 255 235 261 220 297 10 254 246
Peptide XII 77 41 246 224 263 219 267 28 261 226 2122 26
a
“T” represents the helix terminating residue which is the site of chiral reversal. The residue preceding and following T are sequentially
numbered.
b Sequences of peptides and references in parentheses:
Peptide I: Boc–Trp–Ile–Ala–Aib–Ile–Val–Aib–Leu–Aib–Pro–OMe (Ref. 47).
Peptide II: Ac–Trp–Ile–Ala–Aib–Ile–Val–Aib–Leu–Aib–Pro–OMe (Ref. 47).
Peptide III: Boc–Trp–Ile–Ala–Aib–Ile–Val–Aib–Leu–Aib–Pro–OMe (anhydrous; Ref. 48).
Peptide IV: Boc–Trp–Ile–Ala–Aib–Ile–Val–Aib–Leu–Aib–Pro–OMe z 2H2O (Ref. 49).
Peptide V: Boc–Val–Aib–Val–Aib–Val–Aib–Val–OMe (Ref. 50).
Peptide VI: Boc–Val–DPhe–Phe–Ala–Phe–DPhe–Val–DPhe–Gly–OMe (Ref. 51).
Peptide VII: pBrBz–(Aib–Ala)3–OMe (Ref. 52).
Peptide VIII: pBrBz–(Aib–Ala)4–OMe z 2H2O (Ref. 52).
Peptide IX: Boc–Aib–Pro–Val–Aib–Val–OMe (Ref. 53).
Peptide X: pCl–Z–Pro–Aib–Ala–Aib–Ala–OMe (Ref. 54).
Peptide XI: Z–Aib–Ala–Leu–Aib–NHMe (Ref. 55).
Peptide XII: Boc–Phe–DPhe–Val–Phe–DPhe–Val–OMe (Ref. 56).
the observed sample size is relatively small, the ten-
dency of Leu residues to adopt more negative f
values and more positive c values, corresponding to
the bridge region of f,c space, is clearly evident.This
feature has been noted in an earlier analysis based on
fewer structures.29 The structure of peptide X listed in
Table V may be viewed as an exception. Although the
penultimate Aib in the sequence adopts an aL confor-
mation, the preceding residue also adopts an aL con-
formation. The structure may be viewed as a distorted
type II b-turn followed by two consecutive type III9
b-turns.
The structure of peptide XI (Z–Aib–Ala–Leu–
Aib–NHMe) in Table V is an example where despite
the appropriate positioning of an Aib residue at the
C-terminus, chiral reversal and 63 1 hydrogen-bond
formation is not observed. In this case the two inde-
pendent molecules in the crystals adopt conformations
thar lie close to 310- and a-helical structures. Inter-
estingly, in both molecules the Leu residue adopts
backbone dihedral angles significantly deviated from
the idealized helical values (molecule A: f 5 2102°,
c 5 259°; molecule B: f 5 297°, c 5 10°). In
principle, peptide Z–Aib–Ala–Leu–Aib–NHMe rep-
resents the shortest segment in which an idealized
Schellman motif could have formed. An analysis of
the sequences listed in Table V suggests that multiple
factors determine the stereochemistry of the C-termi-
nus in helical peptides. Clearly, energetic differences
between the aR and aL conformations of an achiral
residue placed at the potential helix terminating posi-
tion in peptides are small. The possible role of crystal
packing effects cannot therefore be entirely neglected.
The present analysis suggests that local sequences
may be important in determining whether or not chiral
reversal is observed, when an achiral residue is placed
at the penultimate position of a sequence. The precise
role of chain length and sequence effects in Schellman
FIGURE 3 Distribution of the dihedral angles f and c (in degrees) in residues Leu (top), Val
middle), and Ala (bottom) in helical peptides. The histogram interval is 10°. The sample includes
128 Leu, 86 Val,and 191 Ala residues, from the crystal structures of 71 helical peptides. Helix chain
length varies from six to sixteen residues.
motif formation merits further investigation.
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